SM
BIIB icon

Samantha McLemore’s Biogen BIIB Stock Holding History

Samantha McLemore’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9M Buy
189,400
+187,506
+9,900% +$35.9M 1.34% 29
2026
Q1 		$34.7M Buy
+1,894
New +$349K 1.27% 31

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Samantha McLemore's BIIB Position: Q2 2026 in Review

Samantha McLemore reduced its Biogen (BIIB) stake by 25% in Q2 2026, selling an estimated $18.4M and leaving 283,697 shares worth $61.3M. The position accounts for 2.01% of the portfolio, ranked #22.

Samantha McLemore first reported a position in BIIB in Q1 2024 and has held it in 10 quarters since. The position peaked at $101M in Q4 2025. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Samantha McLemore held 283,697 shares of Biogen worth $61.3M as of Q2 2026.
  • Samantha McLemore sold 96,044 Biogen shares in Q2 2026, an estimated $18.4M.
  • Biogen made up 2.01% of Samantha McLemore's portfolio in Q2 2026, its #22 holding.
  • Samantha McLemore first reported a position in Biogen in Q1 2024 and has held it in 10 quarters since.
  • Samantha McLemore's Biogen position peaked at $101M in Q4 2025.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Patient Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.